Norepinephrine is a catecholamine indicated to raise blood pressure in adult patients with severe, acute hypotension. It is available as injection for intravenous use. MedsAcross supplies Norepinephrine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LEVOPHED is indicated to raise blood pressure in adult patients with severe, acute hypotension. LEVOPHED is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states.
Source: US FDA prescribing information
Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Source: US FDA prescribing information
• Initial dose of 0.25 mL to 0.375 mL (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low to normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation of vital organs. • The average maintenance dose ranges from 0.0625 mL to 0.125 mL per minute (from 2 mcg to 4 mcg of base).
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
• Tissue Ischemia: Avoid extravasation of LEVOPHED into the tissues, as local necrosis might ensue due to the vasoconstrictive action of the drug. Infuse LEVOPHED into a large vein. To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of an adrenergic blocking agent. • Hypotension After Abrupt Discontinuation: Sudden cessation of the infusion rate may result in marked hypotension. Reduce the LEVOPHED infusion rate gradually. • Cardiac Arrhythmias: LEVOPHED may cause arrhythmias. Monitor cardiac function in patients with underlying heart disease. • Allergic Reactions with Sulfite: LEVOPHED contains sodium metabisulfite. Sulfite may cause allergic-type-reactions.
Source: US FDA prescribing information
The following adverse reactions are described in greater detail in other sections: • Tissue Ischemia • Hypotension • Cardiac Arrhythmias The most common adverse reactions are hypertension and bradycardia. The following adverse reactions can occur: Nervous system disorders: Anxiety, headache Respiratory disorders: Respiratory difficulty, pulmonary edema Most common adverse reactions are ischemic injury, bradycardia, anxiety, transient headache, respiratory difficulty, and extravasation necrosis at injection site.
Source: US FDA prescribing information
• Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. • Cyclopropane and halothane anesthetics increase cardiac autonomic irritability.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Store in original carton until time of administration to protect from light.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Norepinephrine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Norepinephrine 4 mg/4 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Norepinephrine 16 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Norepinephrine 4 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Norepinephrine 8 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Norepinephrine 32 mg/250 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
| Levophed 4 mg/4 mL injectionIntravenous | Hospira | US FDA | Available on request |
| Norepinephrine 1 mg/1 mL injectionIntravenousGeneric name | — | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 13 July 1950 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Norepinephrine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Norepinephrine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Norepinephrine, including Levophed.
Yes. The US FDA first approved Norepinephrine on 13 July 1950, according to Drugs@FDA.
No listed presentation of Norepinephrine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Norepinephrine is classified under ATC code C01CA03 (Norepinephrine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.